Home › Breast Cancer › NCT07833566

Biopsy-site-marker in Breast Cancer

Inflammation and Biopsy-site-marker in Breast Cancer (MOSAIC)

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Written informed consent (ICF) signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
* Female patients at \> 18 years of age at the time of signature of the ICF.
* Pathologically verified invasive breast cancer cases referred to OU for surgery.

Exclusion Criteria:

* Patients who had a biopsy at OUBI OKC.
* Patient who will undergo neoadjuvant therapy
* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active viral infection, including hepatitis B, hepatitis C, and human immunodeficiency virus. Screening for chronic conditions is not required.
* Currently pregnant or breastfeeding
* Patients not eligible for surgery
* Prisoners

About the study

The purpose of this study is to explore pro-metastatic changes in breast cancer (BC) associated with the stiffness of biopsy site markers. This study aims to determine whether the stiffness of a biopsy site marker promotes inflammatory changes in breast cancer and to evaluate whether there is a relationship between biopsy site marker stiffness and inflammation.

What is being tested

• Biopsy-Site Marker Placement. (device)

Sponsor: University of Oklahoma · Participants: 140 · Started: Jul 9, 2026

Contact the study team

• Lead Onco Nurse · Phone: 405-271-8777

Official record on ClinicalTrials.gov — NCT07833566

Locations in the U.S.

Conditions

• Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.